Expanded Access Program of AMN107 in Imatinib-resistant or Intolerant Adult Patients With Chronic Myeloid Leukemia
Expanded access is no longer available for this treatment.
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )
First received: March 9, 2006
Last updated: August 25, 2011
Last verified: August 2011
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||Expanded access is no longer available for this treatment.|
|Study Completion Date:||No date given|
|Primary Completion Date:||November 2008 (Final data collection date for primary outcome measure)|
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Zhou L, Meng F, Yin O, Wang J, Wang Y, Wei Y, Hu P, Shen Z. Nilotinib for imatinib-resistant or -intolerant chronic myeloid leukemia in chronic phase, accelerated phase, or blast crisis: a single- and multiple-dose, open-label pharmacokinetic study in Chinese patients. Clin Ther. 2009 Jul;31(7):1568-75. doi: 10.1016/j.clinthera.2009.07.016.